Categories: HealthcareNews

Lumeon Engages Amendola for Strategic PR and Marketing Services

Award-winning Healthcare, Digital Health and Life Sciences PR agency and Care Orchestration Leader Partner to Raise Awareness of Automating Manual Tasks and Empowering Care Teams

SCOTTSDALE, Ariz., July 14, 2022 /PRNewswire/ — Amendola, a nationally recognized, award-winning healthcare technology and life sciences public relations and marketing firm, announced today that Lumeon, the leading care orchestration solution provider, has selected the firm to amplify client successes, thought leadership, and industry best practices.

According to Greg Miller, chief growth officer at Lumeon: “Amendola is part of our success formula for integrated PR and marketing programs that generate results. We selected Amendola to showcase how Lumeon’s capabilities and solutions help providers confront the aftermath of a global pandemic with technology that provides a lifeline to clinicians and care teams facing endless manual tasks, which often prevent them from delivering the most value to their patients.”

Amendola is implementing comprehensive PR and marketing plans to demonstrate Lumeon’s current technology and services, new offerings, accomplishments, customer wins, and industry partnerships.

“Lumeon brings deep automation to the manual tasks in healthcare that keep clinicians and care teams from performing at the top of their licenses, while at the same time, alleviating the burden on care teams that are over-stressed and suffering from burnout,” said Amendola CEO, Jodi Amendola. “The opportunity to represent Lumeon as it grows its U.S. market share is an exciting time for us, and we look forward to being the communications engine to bring this objective to fruition.”

Lumeon is a digital health company that provides a highly configurable care orchestration platform that automates key steps and workflow in care coordination processes. The Lumeon platform integrates data from multiple sources, applies clinical knowledge in real time, and uses intelligent automation to individualize the care of every patient – at scale.  

About Amendola

Amendola is an award-winning, insights-driven public relations and marketing firm that integrates media relations, social media, content and lead gen programs to move healthcare, life sciences/pharma and healthcare IT decision-makers to action. The agency represents some of the industry’s best-known brands as well as groundbreaking startups that are disrupting the status quo. Nearly 90% of its client base represents multi-year clients and/or repeat client executives. Amendola’s seasoned team of PR and marketing pros understand the ongoing complexities of the healthcare ecosystem and provide strategic guidance and creative direction to drive positive ROI, boost reputation and increase market share. Making an impact since 2003, Amendola combines traditional and digital media to fuel meaningful and measurable growth. For more information about the industry’s “A-Team,” visit www.acmarketingpr.com, and follow us on Twitter and LinkedIn.

About Lumeon

Lumeon is a digital health company that provides a highly configurable cloud-based care orchestration platform that automates all steps in the care coordination process. The platform enables care teams to work at top-of-license by delivering the right care, at the right time, addressing the unique needs of every patient. By integrating data from multiple sources, applying clinical knowledge in real time, and using intelligent automation to individualize the care of every patient, Lumeon helps organizations focused on integrating the delivery of care to reduce manual tasks and ease the burden on care teams. To learn more, visit www.lumeon.com.

Media Contact:
Marcia Rhodes
Amendola Communications
mrhodes@acmarketingpr.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lumeon-engages-amendola-for-strategic-pr-and-marketing-services-301586640.html

SOURCE Amendola Communications

Staff

Recent Posts

Vivos Inc.’s IsoPet® Division Achieves Exceptional Growth in 2024, Expanding Certified Veterinary Clinics Nationwide

Richland, WA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to…

13 minutes ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

– ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing…

13 minutes ago

Optinose Announces 1-for-15 Reverse Stock Split

YARDLEY, Pa., Dec. 26, 2024 (GLOBE NEWSWIRE) -- Optinose, Inc. (NASDAQ: OPTN), a pharmaceutical company…

14 minutes ago

TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium

WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage…

14 minutes ago

Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute

Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development…

14 minutes ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or…

14 minutes ago